Royal Bank of Canada Issues Positive Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT - Free Report) had its price objective raised by Royal Bank of Canada from $8.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a sector perform rating on the stock.

Several other equities research analysts also recently issued reports on the company. Stephens cut their price target on Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Thursday, August 8th. JPMorgan Chase & Co. raised their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI raised their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 8th. Finally, Piper Sandler decreased their target price on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating on the stock in a research report on Monday, August 26th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $11.64.

Health Catalyst Trading Up 7.4 %

Shares of Health Catalyst stock traded up $0.61 during trading on Thursday, hitting $8.86. 808,341 shares of the stock were exchanged, compared to its average volume of 562,764. The company has a fifty day moving average price of $8.01 and a 200-day moving average price of $7.11. The stock has a market capitalization of $535.76 million, a price-to-earnings ratio of -5.91 and a beta of 1.32. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. During the same quarter in the previous year, the business earned ($0.21) earnings per share. The business's revenue was up 3.7% compared to the same quarter last year. Equities research analysts forecast that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the firm's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now owns 140,108 shares of the company's stock, valued at approximately $1,062,018.64. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Kevin Lee Freeman sold 7,500 shares of the company's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of the firm's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 35,396 shares of company stock worth $266,280 over the last three months. Corporate insiders own 2.50% of the company's stock.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently added to or reduced their stakes in HCAT. Quest Partners LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC lifted its stake in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock valued at $41,000 after buying an additional 5,232 shares during the period. Quarry LP lifted its stake in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock valued at $45,000 after buying an additional 2,610 shares during the period. nVerses Capital LLC bought a new position in shares of Health Catalyst during the 3rd quarter worth approximately $59,000. Finally, Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the 2nd quarter worth approximately $64,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.